CSL LTD SPON.ADR 2 Market Cap ($40.06 Billion)
Market Cap & Net Worth: CSL LTD SPON.ADR 2 (CSJA)
CSL LTD SPON.ADR 2 market cap. CSL LTD SPON.ADR 2 (F:CSJA) has a market capitalization of $40.06 Billion (€34.26 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #659 globally and #141 in its home market, demonstrating a -9.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CSL LTD SPON.ADR 2's stock price €18.20 by its total outstanding shares 1941275820 (1.94 Billion).
CSL LTD SPON.ADR 2 Market Cap History (2015–2026)
CSL LTD SPON.ADR 2 market cap history from 2015 to 2026. Data shows change from $72.91 Billion to $68.09 Billion (-3.35% CAGR). Check CSL LTD SPON.ADR 2 stock quote for real-time trading data and today's change.
CSL LTD SPON.ADR 2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CSL LTD SPON.ADR 2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CSJA total assets for a full breakdown of the balance sheet.
Latest Price to Sales (P/S) Ratio
7.00x
CSL LTD SPON.ADR 2's market cap is 7.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
35.99x
CSL LTD SPON.ADR 2's market cap is 35.99 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $199.47 Billion | $10.49 Billion | $2.25 Billion | 19.01x | 88.47x |
| 2023 | $195.60 Billion | $13.17 Billion | $2.19 Billion | 14.85x | 89.15x |
| 2024 | $188.37 Billion | $14.69 Billion | $2.64 Billion | 12.82x | 71.30x |
| 2025 | $108.03 Billion | $15.43 Billion | $3.00 Billion | 7.00x | 35.99x |
Competitor Companies of CSJA by Market Capitalization
Companies near CSL LTD SPON.ADR 2 in the global market cap rankings as of October 31, 2026. See CSJA equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to CSL LTD SPON.ADR 2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of CSL LTD SPON.ADR 2 (2015–2026)
Market capitalization of CSL LTD SPON.ADR 2 from 2015 to today. Between 2015 and today, CSL LTD SPON.ADR 2's market cap moved from $72.91 Billion to $ 68.09 Billion, with a yearly change of -3.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €68.09 Billion | -36.97% |
| 2025 | €108.03 Billion | -42.65% |
| 2024 | €188.37 Billion | -3.69% |
| 2023 | €195.60 Billion | -1.94% |
| 2022 | €199.47 Billion | -0.43% |
| 2021 | €200.34 Billion | +5.83% |
| 2020 | €189.30 Billion | -0.50% |
| 2019 | €190.25 Billion | +61.11% |
| 2018 | €118.09 Billion | +24.75% |
| 2017 | €94.66 Billion | +33.48% |
| 2016 | €70.92 Billion | -2.74% |
| 2015 | €72.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of CSL LTD SPON.ADR 2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.06 Billion USD |
| MoneyControl | $40.06 Billion USD |
| MarketWatch | $40.06 Billion USD |
| marketcap.company | $40.06 Billion USD |
| Reuters | $40.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CSL LTD SPON.ADR 2
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more